Ivermectin - an antiviral drug for the COVID-19 pandemic?

Abstract

Abstract
 The use of ivermectin for the treatment of COVID-19 infections has been a subject of significant interest and controversy. The drug has a history of off-label use for a variety of clinical disorders and has shown some potential as an antiviral drug in in vitro studies and animal studies, and it has a relatively favorable safety profile. Multiple studies have been published examining the use of ivermectin against COVID-19. While several studies suggested it could be an effective therapeutic, most of these studies were insufficiently robust, had design flaws, or did not report any changes in important clinical outcomes, such as mortality. A smaller number of more robust studies did not support ivermectin use for COVID-19 treatment. Therefore, at present, ivermectin cannot be recommended for the treatment of COVID-19. While further studies may be warranted, this decision must be weighed against the possibility that this research may not alter current recommendations on the use of ivermectin in COVID-19 infections. 
 
 Keywords: COVID-19; ivermectin; prophylaxis, hospitalization, respiratory failure, mortality

Impact of the COVID-19 pandemic on dispensing medicines in the community pharmacy

“…Nevertheless, its optimal antiviral dose has not been determined, and the preliminary data do not illustrate a clear and comprehensive understanding of its effect in COVID-19. However, its effectiveness as an antivirus is still controversial, whilst latest studies have concluded that ivermectin has no benefit in the treatment of COVID-19 or needs very high and dangerous doses and for very long time [31,32].…”